It has been confirmed that CRGs could predict immunotherapy efficacy for breast cancer.[39] It may provide preliminary evidence for the potential of DLAT in predicting the efficacy of anti-PD-L1 immunotherapy for NSCLC. Here, CD274 is linked to breast cancer.